Rezolute Announces Results From Its Ongoing Open-Label Phase 3 upLIFT Study Of Ersodetug In Tumor Hyperinsulinism; Primary Efficacy Endpoint Has Been Achieved Based On Preliminary Results; Topline Results Expected By Mid-December 2026

Benzinga
Open on Benzinga